HTA58 Does NICE’s STA Process Effectively Reward the Value of Double-Branded Oncology Combinations, When Compared to Oncology Monotherapies?
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1518
https://www.valueinhealthjournal.com/article/S1098-3015(22)03723-8/fulltext
Title :
HTA58 Does NICE’s STA Process Effectively Reward the Value of Double-Branded Oncology Combinations, When Compared to Oncology Monotherapies?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03723-8&doi=10.1016/j.jval.2022.09.1518
First page :
Section Title :
Open access? :
No
Section Order :
11066